Inhibition of the transcription factor ROR-γ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis

Exp Neurol. 2020 Mar:325:113146. doi: 10.1016/j.expneurol.2019.113146. Epub 2019 Dec 12.

Abstract

IL-17 producing CD4 T cells (Th17) cells increase significantly with disease severity in myasthenia gravis (MG) patients. To suppress the generation of Th17 cells, we examined the effect of inhibiting retinoic acid receptor-related-orphan-receptor-C (RORγ), a Th17-specific transcription factor critical for differentiation. RORγ inhibition profoundly reduced Th17 cell frequencies, including IFN-γ and IL-17 co-producing pathogenic Th17 cells. Other T helper subsets were not affected. In parallel, CD8 T cell subsets producing IL-17 and IL-17/IFN-γ were increased in MG patients and inhibited by the RORγ inhibitor. These findings provide rationale for exploration of targeted Th17 therapies, including ROR-γ inhibitors, to treat MG patients.

Keywords: AChR; IL-17; Interferon-gamma; Myasthenia gravis; Receptor-related orphan receptor gamma; Th17 cell.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Autoantibodies / immunology
  • Autoantigens / immunology
  • Cell Differentiation / drug effects
  • Cell Differentiation / immunology
  • Female
  • Humans
  • Immunologic Factors / pharmacology*
  • Interleukin-17 / immunology
  • Male
  • Middle Aged
  • Myasthenia Gravis / immunology*
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / antagonists & inhibitors*
  • Receptors, Cholinergic / immunology
  • Th17 Cells / drug effects*
  • Th17 Cells / immunology*

Substances

  • Autoantibodies
  • Autoantigens
  • IL17A protein, human
  • Immunologic Factors
  • Interleukin-17
  • Nuclear Receptor Subfamily 1, Group F, Member 3
  • Receptors, Cholinergic